BioLineRx Ltd. (TLV:BLRX)

Market Cap	34.07M -36.6%
Revenue (ttm)	4.15M -91.9%
Net Income	-20.82M
EPS	-0.01
Shares Out	2.62B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,113,703
Open	1.300
Previous Close	1.300
Day's Range	1.300 - 1.400
52-Week Range	1.100 - 2.400
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About BioLineRx

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 24
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BLRX

Financial Performance

In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error